Pharmacogenetics and pharmacogenomics: are they still promising?

被引：13

作者：

Pirazzoli, A ^{[1
]}

Recchia, G ^{[1
]}

机构：

[1] GlaxoSmithKline Spa, I-37135 Verona, Italy

来源：

PHARMACOLOGICAL RESEARCH | 2004年 / 49卷 / 04期

关键词：

phamacogenetics; pharmacogenomics; clinical application; new drug discovery;

D O I：

10.1016/j.phrs.2003.04.003

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In the last several years pharmacogenetics and pharmacogenomics have attracted the interest of the scientific community and of important pharmaceutical groups. What is the consequence for medicine and for the pharmaceutical industry? What has emerged from this investment, and what can we expect for the future? As with many new technologies, pharmacogenetics and pharmacogenomics were first adapted with much enthusiasm, and then found to require time and experience, together with sustained investment, before they could take their full place in drug discovery and development. The benefits of these technologies are now emerging, however, and they have become essential tools for the pharmaceutical industry. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：357 / 361

页数：5

共 18 条

[1]

ANDERSON W, 2000, EFFECTS POLYMORPHISI

[2]

*CPMP, 2002, EMEACPMP307001

[3] The economics of gene therapy and of pharmacogenetics [J].